Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990042 | 0.90 | GRM5 (0.52) | GRM5 | |
| SCHEMBL1692176 | 0.90 | GRM5 (0.47) | GRM5 | |
| SCHEMBL990047 | 0.89 | GRM5 (0.53) | GRM5 | |
| SCHEMBL990811 | 0.87 | GRM5 (0.52) | GRM5 | |
| SCHEMBL990750 | 0.86 | GRM5 (0.56) | GRM5 | |
| SCHEMBL990130 | 0.81 | GRM5 (0.47) | GRM5 | |
| SCHEMBL990991 | 0.80 | GRM5 (0.48) | GRM5 | |
| SCHEMBL990801 | 0.80 | GRM5 (0.48) | GRM5 | |
| SCHEMBL990050 | 0.80 | ALDH1A1 (0.48) | GRM5 | |
| SCHEMBL991105 | 0.80 | ALDH1A1 (0.48) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453512-B1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2006-05-31 | — | — | EP | claimed |
| EP-2211859-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2016-01-06 | — | — | EP | disclosed |
| US-20150272929-A1 | ORGANIC COMPOUNDS | UMBRICHT DANIEL (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20140194423-A1 | COMBINATION PRODUCTS | GOMEZ-MANCILLA BALTAZAR (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703809-B2 | Combination products | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20130331568-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2013-12-12 | — | — | US | disclosed |
| US-8536229-B2 | Acetylene derivatives having MGluR 5 antagonistic activity | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20130052644-A1 | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) | NOVARTIS AG (CH) | 2013-02-28 | — | — | US | disclosed |
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1915147-A1 | USE OF MGLUR5 (ESP. AFQ056) IN GI (ESP. GERD) | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-7348353-B2 | Acetylene derivatives having mGluR 5 antagonistic activity | NOVARTIS AG (CH) | 2008-03-25 | — | — | US | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007006530-A1 | USE OF MGLUR5 (ESP. AFQ056) IN GI (ESP. GERD) | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| EP-1453512-B8 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| EP-1453512-B1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-20050065191-A1 | Acetylene derivatives having mglur 5 antagonistic activity | NOVARTIS AG (CH) | 2005-03-24 | — | — | US | disclosed |
| EP-1453512-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | Novartis AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003047581-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331568-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | GRM5, GRM1, GRIK5 | GRM5 1/4885 |
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | GRM5, GRIK5, GRM1 | GRM5 1/4885 |
| US-20050065191-A1 | Acetylene derivatives having mglur 5 antagonistic activity | GRM5, GRM1, GRM2 | GRM5 1/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885 |
| US-20150272929-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | GRM5 1/4885 |
| US-20140194423-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.